Home·ORBIMED SOLUTIONS PRIVATE LIMITED·Products·Measurable residual disease (MRD) testing

Measurable residual disease (MRD) testing

ORBIMED SOLUTIONS PRIVATE LIMITEDGhaziabad, UP

Storefront

Anchored to the MCA registerCIN U32509UP2023PTC190292

Price on request. Ask the factory for a quote.

MOQ not declared by manufacturerLead time not declared by manufacturerCurrency INR

Key attributesAll specs

About this item

Proven leader in measurable residual disease (MRD) testing for lymphoid cancers
clonoSEQ® is trusted by patients, providers, and biopharma companies for clinical care and research
Detects and tracks cancer cells that can remain during and after treatment
Enables clinicians to individualize therapy, lessen treatment burden, and help patients reach treatment goals

Description

Adaptive is a commercial-stage biotechnology company and a proven leader in measurable residual disease (MRD) testing for lymphoid cancers. The company’s primary product is clonoSEQ®, which is trusted by patients, providers, and biopharma companies for both clinical care and research. Powered by next-generation sequencing, clonoSEQ detects and tracks cancer cells that can remain during and after treatment and that may cause disease recurrence. clonoSEQ is shaping modern lymphoid cancer care—enabling clinicians to individualize therapy, lessen treatment burden, and help patients reach their treatment goals.

Reviews

Reviews here come from delivered orders. Only buyers who completed a delivered order can rate this supplier, so the first review appears after the first delivery on BharatSeal.